NASDAQ
2.03USD
-0.19 (-8.56%)
We have scored 3 news catalysts on GlucoTrack, Inc. (GCTK) over the past 12 months. The biggest single-day move next to one of them came Jul 14, 2026, when GCTK closed +14.2%: “Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform”. Coverage across the window leans positive (average ticker sentiment +0.73). Most of the impact sits in sector healthcare and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.6M
P/E
—
EPS
—
Beta
0.62
52W range
1.9977-136.29
Day range
2.00–2.27
Open
2.23
Prev close
2.22
Volume
16.2M
Avg volume
627.6K
Dividend
0.00
IPO
2013-04-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about GlucoTrack, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for GCTK: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlucoTrack, Inc. is a medical device company that focuses on the design, development, and commercialization of novel technologies for people with diabetes. The company is developing the GlucoTrack CBGM, a long-term implantable continuous blood glucose monitoring system for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients.
